AC Immune SA (ACIU) stock
ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.13−0.01 (-0.47%)
Close on Nov 13, 2026Market cap $216.71MP/E –Yield –
AC Immune operating margin
Operating margin is operating income as a percentage of revenue.
AC Immune's operating margin for the twelve months ending Dec 31, 2022 was -1800.4%. For fiscal 2025 it was -1940.1%, against -191.8% the year before. The highest annual figure on record is 47.6% in fiscal 2015.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1940.1% | −1748.3 |
| FY2024 | Dec 31, 2024 | -191.8% | +170.5 |
| FY2023 | Dec 31, 2023 | -362.3% | +1438.1 |
| FY2022 | Dec 31, 2022 | -1800.4% | −1403.4 |
| FY2020 | Dec 31, 2020 | -397.0% | −437.3 |
| FY2019 | Dec 31, 2019 | 40.3% | +757.2 |
| FY2018 | Dec 31, 2018 | -716.9% | −605.6 |
| FY2017 | Dec 31, 2017 | -111.3% | −66.2 |
| FY2016 | Dec 31, 2016 | -45.0% | −92.7 |
| FY2015 | Dec 31, 2015 | 47.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -1484.5% | −452.0 |
| Q2 FY2024 | Jun 30, 2024 | -3051.1% | −2523.1 |
| Q4 FY2022 | Dec 31, 2022 | -1869700.0% | −1869129.5 |
| Q3 FY2022 | Sep 30, 2022 | -342.2% | +434.3 |
| Q4 FY2018 | Dec 31, 2018 | -1032.6% | −1052.0 |
| Q3 FY2018 | Sep 30, 2018 | -528.0% | +369.6 |
| Q2 FY2018 | Jun 30, 2018 | -570.5% | +525.5 |
| Q1 FY2018 | Mar 31, 2018 | -776.5% | −386.0 |
| Q4 FY2017 | Dec 31, 2017 | 19.4% | – |
| Q3 FY2017 | Sep 30, 2017 | -897.6% | – |
| Q2 FY2017 | Jun 30, 2017 | -1096.0% | – |
| Q1 FY2017 | Mar 31, 2017 | -390.5% | – |
See a number that looks wrong?